What is your assessment of the secondary end points -- especially renal markers such as albuminuria -- reported in LEADER that may be drivers of atheroinflammatory CV disease?

What is your assessment of the secondary end points -- especially renal markers such as albuminuria -- reported in LEADER that may be drivers of atheroinflammatory CV disease?

What is your assessment of the results of the secondary end points — especially renal markers such as albuminuria — reported in LEADER that may be drivers of atheroinflammatory CV disease? What about the absence of a cancer signal?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

John Petrie, MD, PhD

John Petrie, MD, PhD

Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland